RxDoctor Payments Data

John Adams, MD

Internal Medicine · Katy, TXNPI 1922006410

Payments from drug & device makers

$359,670in general payments, 2019–2025

Across 1,035 payments — averaging $347.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$108K
  • Acella Pharmaceuticals, LLC$66K
  • Novavax Inc$29K
  • GSK$28K
  • Novo Nordisk AS$26K
  • Astrazeneca UK Limited$26K
  • plus $77K from 54 others

What the payments were for

  • Food & beverage$9,664100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca46$107,833
Acella Pharmaceuticals, LLC35$65,554
Novavax Inc16$29,198
GSK35$28,370
Novo Nordisk AS357$26,114
Astrazeneca UK Limited3$25,959
Alnylam Pharmaceuticals Inc.2$22,381
Chiesi USA, Inc.6$14,917
Mirati Therapeutics, Inc.13$14,333
Avion Pharmaceuticals1$11,075
Pfizer30$5,742
Abbott165$1,995
Novo Nordisk64$1,270
Amgen26$631
Amarin Pharma, Inc.41$550
AbbVie(2 entities)22$468
Lilly USA, LLC23$390
Boehringer Ingelheim8$356
Regeneron Healthcare Solutions, Inc.21$288
Kowa Pharmaceuticals America, Inc.21$228
Corcept Therapeutics9$198
Phathom Pharmaceuticals, Inc.6$193
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$159
Medinc Of Texas1$131
Sumitomo Pharma America, Inc.8$123
Inspire Medical Systems, Inc.2$112
Sanofi-aventis U.S. LLC6$88
Astellas Pharma US Inc6$82
Viatris Specialty LLC3$79
Johnson & Johnson(2 entities)4$64
Esperion Therapeutics, Inc.4$62
Mylan Specialty L.p.2$54
Dexcom, Inc.2$50
Pacira Pharmaceuticals Incorporated2$45
Radius Health, Inc.2$43
Sanofi Pasteur Inc.2$41
Sunovion Pharmaceuticals Inc.3$35
Inogen, Inc.2$33
Biohaven Pharmaceutical Holding Company Ltd.2$32
Mallinckrodt Hospital Products Inc.1$32
Seqirus USA Inc2$27
Merck2$25
Otsuka America Pharmaceutical, Inc.1$24
E.r. Squibb & Sons, L.L.C.1$22
Dynavax Technologies Corporation1$22
Optinose US, Inc.1$21
Bausch Health US, LLC1$20
Medtronic1$20
Exact Sciences1$19
Eisai Inc.1$19
Zyla Life Sciences, Inc.1$18
Novartis1$16
Intercept Pharmaceuticals, Inc.1$15
Eli Lilly1$15
Aimmune Therapeutics, Inc.1$14
Biohaven Pharmaceuticals, Inc.1$14
Photonicare Inc1$13
Idorsia Pharmaceuticals US Inc1$12
Bayer1$12
Althera Pharmaceuticals LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$359,670 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$42,668
Medicare patients
141
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$63,519
EliquisApixaban51$57,998
JardianceEmpagliflozin22$26,423
JanuviaSitagliptin Phosphate17$18,366
MounjaroTirzepatide18$17,930
Repatha SureclickEvolocumab22$16,732
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,556
Tresiba Flextouch U-200Insulin Degludec15$11,958
GemtesaVibegron12$6,665
MyrbetriqMirabegron12$6,426
Rosuvastatin Calcium238$4,132
Ezetimibe69$2,077
Levothyroxine Sodium133$1,699
Gabapentin106$1,594
Telmisartan45$1,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,270$63,51954 claims
PfizerEliquis$5,742$57,99851 claims
Boehringer IngelheimJardiance$356$26,42322 claims
MerckJanuvia$25$18,36617 claims
Lilly USA, LLCMounjaro$390$17,93018 claims
GSKTrelegy Ellipta$28,370$14,55619 claims
Sumitomo Pharma America, Inc.Gemtesa$123$6,66512 claims
Astellas Pharma US IncMyrbetriq$82$6,42612 claims
AbbVieSynthroid, Armour Thyroid$468$2,17842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →